Allogene Therapeutics: Q2 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Wednesday reported a loss of $78 million in its second quarter.
On a per-share basis, the South San Francisco, California-based company said it had a loss of 53 cents.
The results topped Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of 59 cents per share.
The immuno-oncology company posted revenue of $44,000 in the period, falling short of Street forecasts. Four analysts surveyed by Zacks expected $72,000.
In the final minutes of trading on Wednesday, the company's shares hit $4.67. A year ago, they were trading at $12.51.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO
